Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : MedAlliance
Deal Size : $1,135.0 million
Deal Type : Acquisition
Cordis Announces Acquisition of MedAlliance
Details : By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR™ (Sustained Sirolimus Release) drug-eluting balloon for the treatment of coronary artery disease.
Brand Name : Selution SLR
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 18, 2022
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : MedAlliance
Deal Size : $1,135.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?